CLINICAL_TRIALS
trial_result
· 2011-10-06
Clinical Trial Update: Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. [Phase 3]
Summary
Results from a 6-week Phase 3 trial of lurasidone hydrochloride for acute schizophrenia have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sumitomo Pharma America, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2011-10-06